核苷（酸）类似物耐药机制及突变位点研究进展

doi:10.19803/j.1672-8629.2021.08.22

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (8): 795-799.
DOI: 10.19803/j.1672-8629.2021.08.22

核苷（酸）类似物耐药机制及突变位点研究进展

李原华^1,2,3, 葛斐林^2,3,4, 陈容娟², 柏兆方³, 李乐², 赵靖^1,3, 刘妍^2,*, 刘文龙^1#, 肖小河³

¹湖南中医药大学药学院,湖南长沙 410208;
²解放军总医院第五医学中心感染病医学部,北京 100039;
³解放军总医院第五医学中心肝病医学部,北京 100039;
⁴北京中医药大学中药学院,北京 100029

收稿日期:2021-03-10 出版日期:2021-08-15 发布日期:2021-08-17
通讯作者: ^*刘妍,女,博士,副研究员,病毒性肝炎诊疗新技术与发病机制。E-mail：liuyan5360@163.com ^#为共同通信作者。
作者简介:李原华,女,硕士,乙型肝炎病毒等感染性疾病耐药研究。
基金资助:
国家自然科学基金资助项目(81930110); 国家自然科学基金面上项目（81573676）

Research Progress on Nucleos(t)ide Analogues Resistance Mechanism and Mutation Sites

LI Yuanhua^1,2,3, GE Feilin^2,3,4, CHEN Rongjuan², BAI Zhaofang³, LI Le², ZHAO Jing^1,3, LIU Yan^2,*, LIU Wenlong^1#, XIAO Xiaohe³

¹College of Pharmacy, Hunan University of Traditional Chinese Medicine, Changsha Hunan 410208, China;
²Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China;
³Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China;
⁴School of Chinese Materia Medica, Beijing University of Traditional Chinese Medicine, Beijing 100029, China

Received:2021-03-10 Online:2021-08-15 Published:2021-08-17

摘要/Abstract

摘要： 核苷（酸）类似物（nucleos(t)ide analogues, NAs）耐药乙型肝炎病毒（hepatitis B virus, HBV）感染是由长期使用药物后HBV逆转录酶区的基因突变导致。耐药性的出现可导致治疗失败,也是疾病进展的重要原因之一。阐明HBV耐药机制对于药物选择及预后治疗具有重要帮助;梳理HBV耐药的突变位点现状将为进一步探讨耐药HBV的相关风险信号及临床精准防控提供依据。本文就NAs耐药乙肝的分子机制与突变位点研究进行简要综述,旨在为耐药乙肝的治疗提供参考。

关键词: 慢性乙型病毒性肝炎, 核苷（酸）类似物, 耐药变异, 分子机制, 突变位点, 风险信号

Abstract: Nucleos(t)ide analogues (NAs)-resistant hepatitis B is caused by gene mutations in the reverse transcriptase region of hepatitis B virus (HBV) after long-term use of NAs. NAs resistance could lead to treatment failure, and it is also one of the important reasons for liver disease progression. Clarifying the mechanism of HBV NAs resistance is of great help to strategy selection and prognosis treatment; combing the mutation site of HBV NAs resistance will provide the basis for further exploring the risk signals of drug-resistant hepatitis B and clinical precise prevention and control. This review analyzed the molecular mechanism and mutation site of NAs-resistant hepatitis B, hoping to provide a reference for the prevention and treatment of NAs-resistant hepatitis B.

Key words: chronic hepatitis B virus infection, nucleos(t)ide analogues, drug-resistant mutations, molecular mechanism, mutation site, risk signal

中图分类号:

R978.7

李原华, 葛斐林, 陈容娟, 柏兆方, 李乐, 赵靖, 刘妍, 刘文龙, 肖小河. 核苷（酸）类似物耐药机制及突变位点研究进展[J]. 中国药物警戒, 2021, 18(8): 795-799.

LI Yuanhua, GE Feilin, CHEN Rongjuan, BAI Zhaofang, LI Le, ZHAO Jing, LIU Yan, LIU Wenlong, XIAO Xiaohe. Research Progress on Nucleos(t)ide Analogues Resistance Mechanism and Mutation Sites[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 795-799.

参考文献

[1] Wang GQ, Duan ZP, Wang FS, et al.The guidelines of prevention and treatment for chronic hepatitis B (2019 version)[J]. J Prac Hepatol(实用病肝脏杂志), 2020, 23(1): 9-32.
[2] Seto WK, Lo YR, Pawlotsky JM, et al.Chronic hepatitis B virus infection[J]. Lancet, 2018, 392: 2313-2324.
[3] Liu J, Liang W, Jing W, et al.Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238.
[4] Liu Y, Xu ZH, Liu LM, et al.Genotypic and phenotypic characteristics of multidrug-resistant hepatitis B virus infection in Chinese hepatitis B patients[J]. Med J Chin PLA(解放军医学杂志), 2012, 37(6): 539-543.
[5] Zhou Y, Liu Y, Xu D, et al.Characteristics and rescue therapy strategies of multidrug-resistant HBV infection[J]. Infect Dis Info(传染病信息), 2017, 30(2): 109-114.
[6] Ye XL, Liu Y, Xu DP.Research progress of drug-resistant mutations associated with adefovir dipivoxil of hepatitis B virus[J]. J Prac Hepatol(实用肝脏病杂志), 2015, 18(3): 312-316.
[7] De Fraga RS, Van Vaisberg V, Mendes LCA, et al.Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review[J]. J Gastroenterol, 2020, 55: 496-514.
[8] Feng XJ, Huang Y, Chen PS, et al.Market analysis of anti-hepatitis B virus drugs[J]. China Biotechnology, 2019, 39(1): 90-98.
[9] Liu Y, Liu W, Li X, et al.Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients[J]. Antivir Ther, 2014, 19(6): 551-558.
[10] Luo A, Jiang X, Ren H.Entecavir-based combination therapies for chronic hepatitis B: A meta-analysis[J]. Medicine (Baltimore), 2018, 97(51): e13596.
[11] Jaffe A, Brown RS Jr.A review of antiviral use for the treatment of chronic hepatitis B virus infection in pregnant women[J]. Gastroenterol Hepatol (NY), 2017, 13(3): 154-163.
[12] Charlton MR, Alam A, Shukla A, et al.An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia[J]. J Gastroenterol, 2020, 55(9): 811-823.
[13] Locarnini S, Zoulim F.Molecular genetics of HBV infection[J]. Antivir Ther, 2010, 15(suppl 3): 3-14.
[14] Zoulim F, Locarnini S.Hepatitis B virus resistance to nucleos(t)ide analogues[J]. Gastroenterology, 2009, 137(5): 1593-1608.
[15] Zoulim F.Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection[J]. Antiviral Res, 2004, 64(1): 1-15.
[16] Zhou P, Qu SY.Research status of nucleoside (acid) analogues in the treatment of viral drug resistance sites in patients with chronic hepatitis B[J]. Chinese Journal of Integrated Traditional and Western Medi-cine on Liver Diseases(中西医结合肝病杂志), 2020, 30(2): 188-192.
[17] Liu Y, Wang C, Zhong Y, et al.Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection[J]. J Viral Hepat, 2011, 18(4): e29-e39.
[18] Liang LY, Wong GL.Unmet need in chronic hepatitis B management[J]. Clin Mol Hepatol, 2019, 25(2): 172-180.
[19] Wang X, Liu X, Dang Z, et al.Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis b patients: a syste-matic review and meta-analysis[J]. Gut Liver, 2020, 14(2): 232-247.
[20] Amini-Bavil-Olyaee S, Vucur M, Luedde T, et al. Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains[J]. J Virol, 2010, 84(2): 1026-1033.
[21] Huang BX, Liu Y, Fan ZP, et al.Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations[J]. World J Gastroenterol, 2020, 26(35): 5314-5327.
[22] Ma Y, Yuan Y, Ma X, et al.Association between clinical features and ymdd mutations in patients with chronic hepatitis b following lamivudie therapy[J]. Exp Therapeutic Med, 2016, 12(2): 847-853.
[23] Ji D, Liu Y, Li L, et al.The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation[J]. J Clin Virol, 2012, 54(1): 66-72.
[24] Liu Y, Xu Z, Wang Y, et al.rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus[J]. PLoS One, 2014, 9(2): e89015.
[25] Wang C, Yu S, Zhang Y, et al.Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy[J]. Exp Ther Med, 2019,17(4): 2473-2484.
[26] Quercia R, Perno CF, Koteff J, et al.Twenty-five years of lamivudine: current and future use for the treatment of HIV-1 Infection[J]. J Acquir Immune Defic Syndr, 2018, 78(2): 125-135.
[27] Yip TC, Lai JC, Wong GL.Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?[J]. J Gastroenterol, 2020, 55(11): 1023-1036.
[28] Tacke F, Kroy DC.Treatment for hepatitis B in patients with drug resistance[J]. Ann Transl Med, 2016, 4(18): 334.
[29] Chen RJ, Liu Y, Li XD, et al.Analysis for clinical detection and phenotypic features of HBV mutants resistant to both lamivudine and adefovir[J]. J Prac Hepatol(实用肝脏病杂志), 2018, 31(3): 215-219.
[30] Zhao L, Li X, Cheng Y, et al.Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation[J]. Antiv-iral Res, 2018, 154: 26-34.
[31] Yang S, Xing HC, Cheng J.Progress in hepatitis B virus resistance to nucleos(t)ide analogues[J]. Chin J Exp Clin Infect Dis (Electronic Edition)(中华实验和临床感染病杂志(电子版)), 2018, 12(1): 1-6.
[32] Ahn SH, Park YK, Park ES, et al.The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene[J]. J Virol, 2014, 88(12): 6805-6818.
[33] Liu Y, Li X, Xin S, et al.The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil[J]. J Viral Hepat, 2015, 22(3): 328-334.
[34] Liu Y, Zhou Y, Li X, et al.Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice[J]. Emerg Microbes Infect, 2019, 8(1): 354-365.
[35] Yin FF, Wu Z, Fang W, et al.Resistant mutations and quasispecies complexity of hepatitis B virus during telbivudine treatment[J]. J Gen Virol, 2015, 96(11): 3302-3312.
[36] Liu Y, Corsa AC, Buti M, et al.No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment[J]. J Viral Hepat, 2017, 24(1): 68-74.
[37] Buti M, Tsai N, Petersen J, et al.Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection[J]. Dig Dis Sci, 2015, 60(5): 1457-1464.
[38] Cathcart AL, Chan HL, Bhardwaj N, et al.No resisitance to tenofovir alafenanmide detacted through 96 weeks of treatment in patients with chronic hepatitis B infection[J]. Antimicrob Agents Chemothe, 2018, 62(10): 1064-1076.
[39] Mokaya J, Maponga TG, McNaughton AL, et al. Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: an observational case series of South African adults[J]. J Clin Virol, 2020, 129: 104548.
[40] Liu Y, Wang CM, Cheng J, et al.Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility[J]. Chin Med J (Engl), 2009, 122(13): 1585-1586.
[41] Qin B, Budeus B, Cao L, et al.The amino acid substitutions rtP177G and rtF249 A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir[J]. Antiviral Res, 2013, 97(2): 93-100.
[42] Park ES, Lee AR, Kim DH, et al.Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients[J]. J Hepatol, 2019, 70(6): 1093-1102.
[43] Blackard JT, Kwara A, Sherman KE.In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients[J]. J Hepatol, 2019, 71(6): 1259-1260.
[44] Liu Y, Miller MD, Kitrinos KM.Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro[J]. Antiviral Res. 2017,139: 25-31.
[45] Liaw YF, Leung N, Kao JH, et al.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update[J]. Hepatology International, 2008, 2(3): 263-283.
[46] Shao JM, Tang XF, Liu Y, et al.Progress in rescue therapy of tenofovir disoproxil fumarate for chronic hepatitis B patients with suboptimal virologic response to adefovir dipivoxil[J]. Infect Dis Info(传染病信息), 2017, 30(6): 371-375.

核苷（酸）类似物耐药机制及突变位点研究进展

Research Progress on Nucleos(t)ide Analogues Resistance Mechanism and Mutation Sites

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

[1]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[2]	郑宇静, 赵紫楠, 金鹏飞, 赵飞, 胡欣, 张亚同. 基于医疗机构信息系统的卡培他滨致手足综合征不良反应主动监测[J]. 中国药物警戒, 2023, 20(4): 441-443.
[3]	雷超, 王志飞, 谢雁鸣. 基于临床风险信号的含何首乌中药免疫毒性研究进展[J]. 中国药物警戒, 2022, 19(12): 1384-1387.
[4]	李佳怡, 葛斐林, 曹俊岭, 周晓春, 高云娟, 母光頔, 赵旭, 曹博雅, 郭玉明. 抗生素相关肝损伤不良反应特征及合理用药分析[J]. 中国药物警戒, 2021, 18(11): 1020-1024.
[5]	龚立雄, 王长之, 陈超, 杨悦, 陈健刚, 郭慧, 马雪皎, 刘超. 河南省药品生产企业药品不良反应监测品种风险分级与风险管理研究[J]. 中国药物警戒, 2018, 15(3): 169-175.
[6]	陈保生，刘宏菊，刘冰，郭秀英，王海英，马丽萍. 核苷（酸）类似物治疗慢性乙型肝炎的临床观察[J]. 中国药物警戒, 2017, 14(2): 75-77.